Skip to content
DataLookout
Menu

INTENSIFYNCT05603104

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

StatusTerminated
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 19 versions: 18 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: The site in Israel stopped recruitment due to logistic reasons. Other sites are recruiting for 2023-506602-39-00, 2023-506605-19-00, 2023-506617-21-00. Show 6 more changesShow less
    • Final enrollment: 1 participants, under 1% of the 1254 planned
    • Eligibility criteria expanded, about 19 words
    • Primary completion date changed from estimate of Jun 30, 2028 to Jun 24, 2026
    • Secondary endpoints: details revised at 7 of 17 entries
    • Study description expanded, about 13 words
    • Site details revised
  2. Notable Primary and study completion dates: Jun 30, 2026 to Jun 30, 2028
    • Eligibility criteria shortened, about 1 word
    • Study description expanded, about 9 words
    v17
  3. Notable Eligibility criteria shortened, about 3 words
    • Start date changed from estimate of Apr 30, 2025 to Apr 27, 2025
    • Interventions: Clozapine (Drug), Escitalopram (Drug), Esketamine Nasal Product (Drug), Esketamine hydrochloride (Drug), Ketamine Hydrochloride (Drug)… to Bupropion (Drug), Clozapine (Drug), Escitalopram (Drug), Esketamine Nasal Product (Drug), Esketamine hydrochloride (Drug), Ketamine…
    • Secondary endpoints: details revised at 3 of 17 entries
    v16
  4. Notable Start date: Jan 30, 2025 to Apr 30, 2025v15
  5. Notable Eligibility criteria shortened, about 41 words
    • Secondary endpoints: 18 to 17
    v14
Show 12 earlier versionsHide 12 earlier versions
  1. Notable Start date: Sep 30, 2024 to Jan 30, 2025v13
  2. Notable Start date: Jul 31, 2024 to Sep 30, 2024v12
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v11
  4. Notable Start date: Mar 31, 2024 to Jul 31, 2024v10
  5. Minor Secondary endpoints revised (18)v9
  6. Notable Start date: Aug 1, 2023 to Mar 31, 2024v8 Show 4 more changesShow less
    • Eligibility criteria expanded, about 175 words
    • Interventions: Clozapine (Drug), Duloxetine (Drug), Escitalopram (Drug), Esketamine Nasal Product (Drug), Esketamine hydrochloride (Drug), Ketamine… to Clozapine (Drug), Escitalopram (Drug), Esketamine Nasal Product (Drug), Esketamine hydrochloride (Drug), Ketamine Hydrochloride (Drug)…
    • Secondary endpoints: 16 to 18
    • Study description shortened, about 28 words
  7. Minor Study sites: 14 to 1
    • Study description expanded, about 79 words
    v7
  8. Notable Phase: Phase 4 to Phase 3
    • Eligibility criteria expanded, about 80 words
    • Secondary endpoints: 15 to 16
    • Study description expanded, about 145 words
    v6
  9. Minor Interventions: Clozapine (Drug), Duloxetine (Drug), Escitalopram (Drug), Esketamine Nasal Product (Drug), Lamotrigine (Drug), Lithium (Drug), Quetiapine… to Clozapine (Drug), Duloxetine (Drug), Escitalopram (Drug), Esketamine Nasal Product (Drug), Esketamine hydrochloride (Drug), Ketamine…v5
  10. Minor Site contacts updated at 3 of 14 sitesv4
  11. Minor Study sites: 0 to 14v3
  12. Notable Eligibility criteria shortened, about 6 words
    • Study description expanded, about 1,134 words
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in symptom severity
Timeframe: 6 weeks

Secondary (17)

All study samples: to compare changes in the severity and improvement
All study samples: to compare changes in the levels of depression and anxiety
All study samples: to compare changes in cognitive performance #1
All study samples: to compare changes in cognitive performance #2
All study samples: to compare changes in cognitive performance #3
Show 12 moreShow less
All study samples: to compare changes in cognitive performance #4
All study samples: to compare changes in functioning measure #1
All study samples: to compare changes in functioning measure #2
All study samples: to compare changes in quality of life #1
All study samples: to compare changes in quality of life #2
All study samples: to compare presence of side effects
All study samples: to compare use of concomitant medication
All study samples: to compare premature treatment discontinuation
Schizophrenia sample: to compare changes in Positive and Negative syndrome subscale scores
All study samples: comparison of the proportion of participants (EIPT vs. TAU) that is remission at visit 4.
All study samples: To compare changes in suicidal ideation between treatment arms.
BD study sample: To compare occurrence of (hypo)manic episode during the study between the treatment arms using the Young Mania Rating Scale

Arms and interventions

Schizophrenia EIPT: Switch to clozapineExperimental

Schizophrenia randomized to EIPT: Switch to clozapine. Brand, dosage, frequency and duration up to the investigator's discretion

Schizophrenia TAU: second-line antispychoticActive comparator

Schizophrenia randomized to TAU: switch to second-line antispychotic. Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC)

Major Depressive Disorder EIPT: second-line antidepressant + esketamine nasal sprayExperimental

Major depressive disorder randomized to EIPT: Switch to second-line antidepressant + esketamine nasal spray or (es)ketamine infusion. Antidepressant: Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC). Esketamine nasal spray: 2 times per week for 4 weeks. Initial dose 28 mg, after that increases can be made with 28 mg per increase (up to 84 mg per week). This decision is up to the investigator's discretion (in accordance with SmPC). (Es)ketamine infusion: performed twice weekly for 4 weeks. Compound, brand up to the investigator's discretion (in accordance with SmPC).

Major Depressive Disorder TAU: second-line antidepressantActive comparator

Major depressive disorder randomized to TAU: Switch to second-line antidepressant + esketamine nasal spray or ketamine IV or esketamine IV . Antidepressant: Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC).

Bipolar Depression EIPT: Switch to one of the following combinations:Experimental

Bipolar Depression randomized to EIPT: Switch to 1. one of the following: escitalopram, sertraline, bupropion or venlafaxine plus 2. two of the following: lithium, valproate acid or quetiapine

Bipolar Depression TAU: Switch to quetiapine plus lithium or valproate acid or lamotrigineActive comparator

Bipolar Depression randomized to TAU: Switch to quetiapine plus lithium or valproate acid Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC).

Drugs: Clozapine, Esketamine Nasal Product, Escitalopram, Sertraline, Venlafaxine, Lithium, Valproate acid, Quetiapine, Second-line Antidepressants, Second-line Antipsychotics, Ketamine Hydrochloride, Esketamine hydrochloride, Bupropion

Sites

1 site in 1 country

  • Sheba Medical CenterRamat Gan, Israel